Advancing the health and well-being of animals and people

Comparison of Standard of Care (SOC) and SOC Followed by Investigational Agent for Dogs with Osteosarcoma


Canine appendicular (limb) osteosarcoma is an aggressive cancer that causes local bone destruction and spreads easily to other organs. Better therapies are needed to prevent or delay this spread and extend lives. Cornell University College of Veterinary Medicine, in conjunction with the Comparative Oncology Trial Consortium, is offering a new clinical trial to help treat dogs with osteosarcoma. The purpose of this study is to enroll newly diagnosed dogs to compare standard of care therapy (SOC) to SOC therapy with the addition of a new drug. The goal is to determine the ability of this investigational drug to delay the cancer from spreading to other organs. Dogs enrolled will be followed until this occurs.

ELIGIBILITY: Dogs must be at least 55 pounds, been newly diagnosed with appendicular osteosarcoma by histology or cytology, and have received no prior therapy (chemotherapy, radiation therapy, or bisphosphonate administration). Dogs should have measurable disease of a long bone in a limb (radius, humerus, ulna, femur, and tibia) that is able to be surgically removed via amputation and there can be no evidence of disease spread at the time of enrollment. Initial evaluation and staging diagnostics must be performed at the Cornell University Hospital for Animals (CUHA) to determine final eligibility.

COMPENSATION: For enrolling in the clinical trial a $1,000 credit is provided for amputation. The study then covers office visits for scheduled appointments for chemotherapy and drug treatments; the chemotherapy and investigational drug and their associated administration costs; bloodwork at appointments to receive chemotherapy and investigational drug; hospitalization costs associated with blood measurements of the investigational drug; and x-rays at specific time intervals.

OWNER RESPONSIBILITIES: The owner is responsible for the initial office visit, staging diagnostics to determine eligibility, as well as any surgical costs above the $1,000 credit. Owners must return to CUHA for follow-up appointments, chemotherapy and investigational drug visits (up to 12 visits are required.) Owners must be willing to adhere to the administration and recording guidelines for the investigational drug at home. The owner is also responsible for any post-chemotherapy blood work tests.

CONTACT/SCHEDULE AN APPOINTMENT: Please call the clinical research coordinator or any member of the oncology team at 607-253-3060, or email

Printable flyer (PDF)